CLINICAL TRIALS PROFILE FOR LONAFARNIB
✉ Email this page to a colleague
All Clinical Trials for lonafarnib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003956 ↗ | Combination Chemotherapy in Treating Patients With Advanced Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | 1999-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SCH 66336, fluorouracil, and leucovorin in treating patients who have advanced cancer. |
| NCT00003956 ↗ | Combination Chemotherapy in Treating Patients With Advanced Cancer | Completed | Memorial Sloan Kettering Cancer Center | Phase 1 | 1999-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SCH 66336, fluorouracil, and leucovorin in treating patients who have advanced cancer. |
| NCT00005030 ↗ | SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver | Withdrawn | National Cancer Institute (NCI) | Phase 1 | 1999-09-29 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to compare the effectiveness of different doses of SCH 66336 before surgery in treating patients who have colorectal cancer that has metastasized to the liver. |
| NCT00005030 ↗ | SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver | Withdrawn | M.D. Anderson Cancer Center | Phase 1 | 1999-09-29 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to compare the effectiveness of different doses of SCH 66336 before surgery in treating patients who have colorectal cancer that has metastasized to the liver. |
| NCT00006351 ↗ | SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract | Completed | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | 2000-06-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SCH 66336 and gemcitabine may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of SCH 66336 plus gemcitabine in treating patients who have advanced cancer of the urinary tract. |
| NCT00015899 ↗ | SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors | Completed | National Cancer Institute (NCI) | Phase 1 | 2002-01-01 | RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors. |
| NCT00015899 ↗ | SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors | Completed | Pediatric Brain Tumor Consortium | Phase 1 | 2002-01-01 | RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for lonafarnib
Condition Name
Clinical Trial Locations for lonafarnib
Trials by Country
Clinical Trial Progress for lonafarnib
Clinical Trial Phase
Clinical Trial Sponsors for lonafarnib
Sponsor Name
